Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2014 Q2- Text added to 2014 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
accidental, acetonide, air, Alimera, anacetrapib, appeal, asset, Aventisub, Barcelona, Baylor, Bispecific, Breakthrough, broader, CETP, childbearing, cholesterylester, College, concomitantly, CSwNP, CT, CV, description, dexamethasone, disagree, dismissing, disturbance, domestic, drip, endoscopic, entirety, EPO, ESC, Esperion, evacetrapib, explicit, Fifty, float, foregoing, goodwill, hearing, hoc, Iluvien, image, implant, implicate, imposition, inadvertently, incremental, intranasal, IRS, Labour, LIBERTY, loading, luocinolone, mandated, matter, maximally, media, Merck, MHLW, Ministry, mitigation, mix, MONARCH, myalgia, nominal, nose, novelty, NPS, opposed, oropharyngeal, Orphan, overdose, Ozurdex, Pacific, policy, Polyp, pooled, Portability, post, postmarket, postnasal, practice, prejudice, quoted, ranibizumab, reinstating, Rheumatology, RSV, runny, satisfactory, scan, Schedule, sense, sleep, slower, smell, Spain, spray, stable, stipulation, strict, subcutaneously, sued, surgery, syncytial, University, voluntary, Welfare, women
Valuein 2014 Q2 filing- Value in 2014 Q3 filing
Original filings
Filing view